Daily Archives: August 1, 2018

CORRECTION FROM SOURCE: Transport Canada Certifies 90-Seat Cabin Configuration for Bombardier’s Q400 Aircraft

  • Launch customer SpiceJet of India to become first airline to take advantage of the extra-capacity turboprop’s increased profitability potential

TORONTO, Aug. 01, 2018 (GLOBE NEWSWIRE) — This document corrects and replaces the press release that was sent today at 9:00 am EDT.

Bombardier Commercial Aircraft announced today that its 90-passenger Q400 aircraft configuration has received its certification from Transport Canada, becoming the first in-production commercial turboprop in the world to reach that capacity.

“With increasing growth in the number of passengers per departure in the turboprop market, we are excited to offer our customers a higher-capacity configuration and 15 percent lower cost per seat compared to the previous standard Q400, leading to more profitability potential for airlines,” said Todd Young, Head of the Q Series Aircraft Program, Bombardier Commercial Aircraft. “This milestone certification showcases — once again — the unique versatility of the Q400 turboprop and our continued commitment to the evolution of the program.

“Upon delivery later this year, our launch customer SpiceJet will become the first airline to take advantage of the profitable and efficient operations of the 90-seat Q400 aircraft following its order of up to 50 in 2017,” added Mr. Young.

Combined with the Q400 aircraft’s unique speed flexibility, which is driving higher scheduling efficiency, this new segment solution is perfectly adapted to high-demand turboprop markets and will further enhance economic connectivity between smaller towns and major hubs.

The 90-seat configuration represents another step in Bombardier’s continuous improvement of its Q400 aircraft, aimed at addressing traffic growth and customer bottom line. Other improvements under development includes a 2,000-lb-increase in payload capacity and an escalation of the A-Check and C-Check intervals from 600/6,000 to 800/8,000 flight hours.

About Bombardier
With over 69,500 employees across four business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montreal, Canada, Bombardier has production and engineering sites in 28 countries across the segments of Transportation, Business Aircraft, Commercial Aircraft and Aerostructures and Engineering Services. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2017, Bombardier posted revenues of $16.2 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

Notes to Editors
An image of the Q400 aircraft is posted with this news release at www.bombardier.com.

The Q400 aircraft backgrounder is available in the BCA Media Hub.

Follow @BBD_Aircraft on Twitter to receive the latest news and updates from Bombardier Commercial Aircraft.

To receive our press releases, please visit the RSS Feed section of Bombardier’s Website.

Bombardier, Q400 and Q Series are trademarks of Bombardier Inc. or its subsidiaries.

For Information

Nathalie Siphengphet
Head of Communications and Public Relations

Bombardier Commercial Aircraft
+1(450) 476-5792
nathalie.siphengphet@aero.bombardier.com
www.bombardier.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/07937458-f0aa-4808-bf5c-96f52f5ed9f1

Williams Scotsman to Announce Second Quarter 2018 Results on August 7, 2018

BALTIMORE, Aug. 01, 2018 (GLOBE NEWSWIRE) — WillScot Corporation (Nasdaq: WSC) (“Williams Scotsman”) today announced that it will release its second quarter 2018 financial results Tuesday, August 7, 2018 after the markets close.

President and Chief Executive Officer, Brad Soultz, and Chief Financial Officer, Tim Boswell, will host a conference call and webcast on Wednesday, August 8, 2018 at 10:00 a.m. EDT to discuss the results.

The live call can be accessed by dialing (855) 312-9420 (U.S./Canada toll-free) or (210) 874-7774 (international). A live webcast will also be accessible via the “Events & Presentations” section of the Company’s Investor Relations website https://investors.willscot.com. An archived version of the webcast will be available for 60 days following the call.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is a specialty rental services market leader providing innovative modular space and portable storage solutions across North America. WillScot is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, its branch network includes over 100 locations, its fleet comprises nearly 100,000 modular space and portable storage units, and its customer base has grown to approximately 35,000.

Additional Information and Where to Find It

Additional information about Williams Scotsman can be found on the Williams Scotsman investor relations website at https://investors.willscot.com.

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com 

Media Inquiries:

Scott Junk
scott.junk@willscot.com 

CORRECTING and REPLACING — Neuralstem, Inc.

GERMANTOWN, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) — In a release issued yesterday by Neuralstem, Inc. (Nasdaq:CUR), please note the headline should be, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke,” rather than, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke,” as originally issued. The corrected release follows:

Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced the initiation of a Phase 2 clinical trial evaluating NSI-566, the Company’s lead neural stem cell candidate, as a potential treatment for ischemic stroke.

Neuralstem announced the positive topline results of Phase 1 stroke study in the 2018 ISSCR (International Society for Stem Cell Research) abstract on June 23, 2018.

“The Phase 2 study, which will be a randomized, double-blind, controlled study, is based on the encouraging results from the open-label Phase 1 safety study.  It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralyzed,” said Dr. Karl Johe, Chief Scientific Officer of Neuralstem.

The trial will be taking place at Bayi Brain Hospital in Beijing, China, commencing on August 1, 2018.  Managing the trial will be James Li, Ph.D., Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, a wholly owned subsidiary of Neuralstem, Inc., located in Suzhou, China.  Dr. Li has been made the Manager and a Registered Agent of Suzhou Neuralstem.

Neuralstem will be allocating US$3 million toward this trial.

About Ischemic Stroke

Ischemic strokes, the most common type of stroke, occur as a result of an obstruction within a blood vessel supplying blood to the brain. Approximately 15 million people worldwide suffer stroke of which it is estimated that 87% of all strokes are ischemic strokes. Post-stroke motor deficits include paralysis in arms and legs and can be permanent.

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The Company has two lead development candidates:

  • NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and chronic spinal cord injury (cSCI).
  • NSI-189, is a small molecule in clinical development for major depressive disorder and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Cautionary Statement Regarding Forward Looking Information

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact:

Argot Partners (Investor Relations)
212-600-1902
neuralstem@argotpartners.com

Luxury Brand House of Sillage Launches Limited-Edition Lipstick Case & Refill With Diamond Powder

Also Wins Award for Product Innovation, Luxury Item at the ICMAD City Awards

NEWPORT BEACH, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) — House of Sillage a leader in luxury haute parfumerie, is excited to announce its expansion into cosmetics with its limited-edition lipstick case and refill. Available exclusively at select Neiman Marcus stores and online from August 1st, each limited-edition lipstick comes in a stunning bow-shaped protective carrying case finished in black or white enamel and is encrusted with over three hundred brilliant diamond-cut Swarovski crystals. The lipstick case includes a mirror for effortless precision application.House of Sillage limited-edition lipstick

Known as an industry trailblazer because of how the brand utilizes jewelry and fashion inspired material when cultivating extraordinary fragrance and cosmetic packaging, House of Sillage has continued to evolve this groundbreaking trend with its limited-edition lipstick collection.

Founder & CEO, Nicole Mather designed this new line and wanted to celebrate the essence and power behind the iconic symbol of the bow. “We wanted to pay homage to the bow’s timeless inspiration towards femininity. We’ve seen a bow’s beauty and glory across decades of popular culture and we believe we’ve translated the beauty of our fragrance packaging into cosmetics.”

These ravishing new lipsticks are infused with the highest quality and genuine diamond powder creating a luminous aura of regal beauty. The product names are inspired by royal lineage, which matches the exclusive composition of rich opulent colors brilliantly illuminated in a range of stunning shades (14 to be exact). From Duchess, to Queen, or Countess, product users can match the color that suits their mood of the day and enjoy an ultra-creamy satine texture with a luxe-finished lip, creating the ultimate color pay-off.

HOT OFF THE PRESS
The House of Sillage Limited Edition Lipstick also won its first award this week for Product Innovation, Luxury Item at the ICMAD (Independent Cosmetic Manufacturers and Distributors) City Awards, hosted at the Mandalay Bay in Las Vegas on July 30th, 2018. An incredible achievement considering this is the brand’s first dive into cosmetics!House of Sillage limited-edition lipstick

The Limited Edition Lipstick will also be available in-store at Bergdorf Goodman from September 1st, 2018.

ABOUT HOUSE OF SILLAGE
House of Sillage is based in Newport Beach, California and products are produced in France and Italy. The brand creates fragrances and cosmetics that transcend the binds of sensory expression, steeped in the craftsmanship and composition of the Perfumers savoir-faire. Under the guidance of Founder, Nicole Mather, House of Sillage is dedicated to maintaining and surpassing the true definitions of luxury.

Come visit with us at http://www.houseofsillage.com and follow us on Instagram, Facebook and Twitter.

ABOUT NEIMAN MARCUS GROUP
Neiman Marcus Group LTD LLC is a luxury, multi-branded, omni-channel fashion retailer conducting integrated store and online operations under the
Neiman MarcusBergdorf Goodman, Last Call, Horchow, CUSP and mytheresa brand names. For more information, https://www.neimanmarcus.com

Keep up with the latest news and events happening at Neiman Marcus by becoming a fan on Facebook, following us on Twitter, Instagram, Pinterest and Snapchat.

House of Sillage
Tel: +1.949.200.9265
sophie@houseofsillage.com

Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ca09b8eb-9047-4c29-a677-8be04a67db40
http://www.globenewswire.com/NewsRoom/AttachmentNg/6914ed36-fe75-47fa-8e2a-772a382a4d6a

Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke

GERMANTOWN, Md., July 31, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced the initiation of a Phase 2 clinical trial evaluating NSI-566, the Company’s lead neural stem cell candidate, as a potential treatment for ischemic stroke.

Neuralstem announced the positive topline results of Phase 1 stroke study in the 2018 ISSCR (International Society for Stem Cell Research) abstract on June 23, 2018.

“The Phase 2 study, which will be a randomized, double-blind, controlled study, is based on the encouraging results from the open-label Phase 1 safety study.  It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralyzed,” said Dr. Karl Johe, Chief Scientific Officer of Neuralstem.

The trial will be taking place at Bayi Brain Hospital in Beijing, China, commencing on August 1, 2018.  Managing the trial will be James Li, Ph.D., Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, a wholly owned subsidiary of Neuralstem, Inc., located in Suzhou, China.  Dr. Li has been made the Manager and a Registered Agent of Suzhou Neuralstem.

Neuralstem will be allocating US$3 million toward this trial.

About Ischemic Stroke

Ischemic strokes, the most common type of stroke, occur as a result of an obstruction within a blood vessel supplying blood to the brain. Approximately 15 million people worldwide suffer stroke of which it is estimated that 87% of all strokes are ischemic strokes. Post-stroke motor deficits include paralysis in arms and legs and can be permanent.

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The Company has two lead development candidates:

  • NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and chronic spinal cord injury (cSCI).
  • NSI-189, is a small molecule in clinical development for major depressive disorder and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Cautionary Statement Regarding Forward Looking Information

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact:

Argot Partners (Investor Relations)
212-600-1902
neuralstem@argotpartners.com

WillScot Announces Pricing of $300 Million Senior Secured Notes Offering

BALTIMORE, July 31, 2018 (GLOBE NEWSWIRE) — WillScot Corporation (Nasdaq:WSC) (“WillScot”), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that its indirect subsidiary Mason Finance Sub, Inc. (“Issuer) has priced its offering of $300 million in aggregate principal amount of 6.875% senior secured notes due 223 (the “Notes”) at an issue price of 100% of the aggregate principal amount of the Notes. WillScot intends to use the offering proceeds, together with funds from other sources, to finance its pending acquisition of Modular Space Holdings, Inc. (the “ModSpace Acquisition”) and to pay related fees and expenses.

The Issuer, a wholly-owned subsidiary of Williams Scotsman International, Inc. (“WSII”), was formed to issue notes to help finance the ModSpace Acquisition. If the offering is consummated, the initial purchasers will deposit the gross offering proceeds into an escrow account. Upon consummation of the ModSpace Acquisition and the satisfaction of other conditions, the escrowed proceeds will be released to fund the cash consideration payable by WSII in the ModSpace Acquisition and to pay related fees and expenses.  Upon the closing of the ModSpace Acquisition, the Issuer will also merge with and into WSII, with WSII continuing as the surviving corporation, and WSII will assume the obligations of the Issuer under the Notes and the indenture governing the Notes. If the ModSpace Acquisition is not completed by a specified date or certain other events occur, the Notes will be subject to a special mandatory redemption.

The Notes are being offered in a private placement transaction to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States in accordance with Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  This press release does not constitute an offer to sell any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer or sale would be unlawful.

WillScot expects the offering to close on August 6, 2018, subject to customary closing conditions.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although WillScot believes that these forward-looking statements are based on reasonable assumptions, it can give no assurance that any such forward-looking statement will materialize. Important factors that may affect actual results or outcomes include, among others, our ability to timely satisfy or waive the conditions that must be timely satisfied or waived to close the Notes offering and the ModSpace Acquisition, our ability to raise the capital required to finance the ModSpace Acquisition, including the additional debt financing; and such other risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K for the year ending December 31, 2017). Any forward-looking statement speaks only at the date which it is made, and WillScot disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is a specialty rental services market leader providing innovative modular space and portable storage solutions across North America. WillScot is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, its branch network includes over 100 locations, its fleet comprises nearly 100,000 modular space and portable storage units, and its customer base has grown to approximately 35,000.

Contact Information

Investor Inquiries:
Mark Barbalato
investors@willscot.com

Media Inquiries:
Scott Junk
scott.junk@willscot.com

US supports peaceful settlement of dispute: Congressman

The Chairman of the Subcommittee on Asia and the Pacific of the US House Foreign Affairs Committee, said the US has always focused on the process of which the overlapping sovereignty claims are resolved, supporting the peaceful settlement of dispute according to lawful procedures by non-coercive measures.

Congressman Ted Yoho made the statement at the 8th annual conference on the East Sea, held by the Centre for Strategic and International Studies (CSIS) in Washington DC. Other delegates agreed that militarization of structures in the East Sea has intensified tensions and challenged Southeast Asian nations and the wider region. A Vietnamese representative affirmed Vietnam’s consistent view to work with the international community to reach peaceful solutions to the East Sea issue.

Source: VOV5